• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Banks
    Finance
    Savings Institutions
    Finance
    Get the next $BHLB alert in real time by email

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT).

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date 

    Index Name 

    Action 

    Company Name 

    Ticker 

    GICS Sector 

    September 2, 2025 

    S&P MidCap 400 

    Addition 

    Elanco Animal Health 

    ELAN 

    Health Care 

    September 2, 2025 

    S&P MidCap 400

    Deletion 

    Sarepta Therapeutics 

    SRPT 

    Health Care 

    September 2, 2025 

    S&P SmallCap 600 

    Addition 

    Sarepta Therapeutics 

    SRPT 

    Health Care 

    September 2, 2025 

    S&P SmallCap 600

    Deletion

    Brookline Bancorp

    BRKL

    Financials

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected] 

    Media Inquiries

    [email protected] 

    Cision View original content:https://www.prnewswire.com/news-releases/elanco-animal-health-set-to-join-sp-midcap-400-sarepta-therapeutics-to-join-sp-smallcap-600-302539403.html

    SOURCE S&P Dow Jones Indices

    Get the next $BHLB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHLB
    $BRKL
    $ELAN
    $SPGI

    CompanyDatePrice TargetRatingAnalyst
    Sarepta Therapeutics Inc.
    $SRPT
    12/9/2025$32.00Outperform
    Wedbush
    Elanco Animal Health Incorporated
    $ELAN
    12/9/2025$30.00Overweight
    Barclays
    Elanco Animal Health Incorporated
    $ELAN
    11/21/2025$27.00Overweight
    KeyBanc Capital Markets
    Elanco Animal Health Incorporated
    $ELAN
    11/19/2025$25.00Hold → Buy
    Argus
    Sarepta Therapeutics Inc.
    $SRPT
    11/5/2025$26.00Neutral → Outperform
    Mizuho
    Elanco Animal Health Incorporated
    $ELAN
    10/7/2025$24.00Neutral → Overweight
    Analyst
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    Sarepta Therapeutics Inc.
    $SRPT
    9/22/2025$50.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Joly Hubert claimed ownership of 165 shares (SEC Form 3)

    3 - S&P Global Inc. (0000064040) (Issuer)

    1/9/26 4:02:02 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Director Washington Gregory N

    4 - S&P Global Inc. (0000064040) (Issuer)

    1/6/26 4:10:32 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Director Morris Maria R

    4 - S&P Global Inc. (0000064040) (Issuer)

    1/6/26 4:09:42 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Sarepta Therapeutics with a new price target

    Wedbush initiated coverage of Sarepta Therapeutics with a rating of Outperform and set a new price target of $32.00

    12/9/25 8:53:25 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Elanco Animal Health with a new price target

    Barclays initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $30.00

    12/9/25 8:46:01 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KeyBanc Capital Markets initiated coverage on Elanco Animal Health with a new price target

    KeyBanc Capital Markets initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $27.00

    11/21/25 8:08:36 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    SEC Filings

    View All

    Sarepta Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

    12/19/25 4:34:54 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - S&P Global Inc. (0000064040) (Filer)

    12/16/25 4:05:25 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    SEC Form 8-K filed by Sarepta Therapeutics Inc.

    8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

    12/11/25 7:13:42 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $478,496 worth of shares (22,000 units at $21.75) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:41:24 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Modi Rajeev A. bought $95,985 worth of shares (4,500 units at $21.33), increasing direct ownership by 4% to 123,082 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:43:23 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    S&P Global Schedules Fourth Quarter and Full-Year 2025 Earnings Announcement and Conference Call for Tuesday, February 10, 2026

    NEW YORK, Jan. 9, 2026 /PRNewswire/ -- S&P Global's (NYSE: SPGI) fourth quarter and full-year 2025 results will be issued on Tuesday, February 10, 2026 via news release at approximately 7:15 a.m. Eastern Time. The news release will be available at www.spglobal.com. Martina Cheung, President and CEO; Eric Aboaf, Chief Financial Officer; and Mark Grant, Senior Vice President, Investor Relations and Treasurer, will host a conference call and webcast at 8:30 a.m. Eastern Time on February 10, 2026 to discuss the Company's fourth quarter and full-year 2025 financial results. The presentation is open to all interested parties and may include forward-looking information. The presenters' slides, sup

    1/9/26 2:42:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    'Substantial Shortfall' in Copper Supply Widens as the Race for AI and Growing Defense Spending Add to Accelerating Demand, New S&P Global Study Finds

    Supply deficit would reach 10 million metric tons by 2040 as demand surges 50% WASHINGTON, Jan. 8, 2026 /PRNewswire/ -- A looming copper supply gap is poised to widen as electricity demand accelerates and new vectors—such as the race for artificial intelligence and surging defense spending—add to the call on copper. According to Copper in the Age of AI: The Challenges of Electrification, a comprehensive new study by S&P Global (NYSE:SPGI), the emerging supply deficit constitutes a "systemic risk for global industries, technological advancement and economic growth." The study f

    1/8/26 7:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Dow Jones Indices Reports U.S. Common Indicated Dividend Payments Increase of $13.1 Billion in Q4 2025 and $46.4 Billion for 2025

    Q4 2025 U.S. common dividend increases were $16.1 billion, up 14.9% from $14.0 billion in Q3 2025 and up 13.0% from $14.2 billion in Q4 2024.Q4 2025 U.S. common dividend decreases were $3.0 billion, down 12.4% from $3.4 billion in Q3 2025 and up 20.5% from $2.5 billion in Q4 2024.Q4 2025 net indicated dividend rate change increased $13.1 billion. For 2025 U.S. common dividend increases were $59.3 billion, down 16.9% from the 2024 period's $71.4 billion; decreases were down 28.8% to $12.9 billion compared to $18.1 billion for the prior 12-month period.The net 2025 indicated dividend increase was $46.4 billion compared to $45.1 billion for the 12-months ending September 2025 and $53.3 billion

    1/7/26 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Leadership Updates

    Live Leadership Updates

    View All

    UiPath Set to Join S&P MidCap 400 and Versant Media Group to Join S&P SmallCap 600

    NEW YORK, Dec. 23, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600:  UiPath Inc. (NYSE:PATH) will replace Synovus Financial Corp. (NYSE:SNV) in the S&P MidCap 400 effective prior to the opening of trading on Friday, January 2. S&P MidCap 400 constituent Pinnacle Financial Partners Inc. (NASD: PNFP) is acquiring Synovus Financial Corp in a deal expected to be completed soon, pending final closing conditions.Versant Media Group Inc. (NASD: VSNT) will replace Brandywine Realty Trust (NYSE:BDN) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 6. S&P 500 constituent Comcast Corp. (NASD: CMCSA)

    12/23/25 5:55:00 PM ET
    $BDN
    $CMCSA
    $PATH
    Real Estate Investment Trusts
    Real Estate
    Cable & Other Pay Television Services
    Telecommunications

    S&P Global Adds Hubert Joly to its Board of Directors

    NEW YORK, Dec. 16, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) announced today that its Board of Directors has approved the addition of Mr. Hubert Joly to the Board, effective January 2, 2026. Mr. Joly is the former Chair and Chief Executive Officer at Best Buy and is now a senior lecturer at Harvard Business School. Earlier in his career, Mr. Joly served as President and CEO of Carlson, a global hospitality and travel company. In addition to his teaching post at Harvard, Mr. Joly is a member of the Board of Directors of Johnson & Johnson and was until recently on the Board of

    12/16/25 8:05:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Announces Mobility Business Chief Financial Officer

    Matt Calderone, outgoing CFO of Booz Allen, named new CFO of Mobility and will lead the finance function of the standalone company NEW YORK, Dec. 16, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the appointment of Matt Calderone as Chief Financial Officer (CFO) of the Mobility business, joining the company by March 1, 2026. Mr. Calderone will serve as the CFO of the standalone public company through its planned separation from S&P Global and will oversee all aspects of the company's Finance function. He will report to Mr. Bill Eager, President of S&P Global Mobility, and CEO-designate of the future standalone company.

    12/16/25 7:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Financials

    Live finance-specific insights

    View All

    S&P Global Schedules Fourth Quarter and Full-Year 2025 Earnings Announcement and Conference Call for Tuesday, February 10, 2026

    NEW YORK, Jan. 9, 2026 /PRNewswire/ -- S&P Global's (NYSE: SPGI) fourth quarter and full-year 2025 results will be issued on Tuesday, February 10, 2026 via news release at approximately 7:15 a.m. Eastern Time. The news release will be available at www.spglobal.com. Martina Cheung, President and CEO; Eric Aboaf, Chief Financial Officer; and Mark Grant, Senior Vice President, Investor Relations and Treasurer, will host a conference call and webcast at 8:30 a.m. Eastern Time on February 10, 2026 to discuss the Company's fourth quarter and full-year 2025 financial results. The presentation is open to all interested parties and may include forward-looking information. The presenters' slides, sup

    1/9/26 2:42:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Dow Jones Indices Reports U.S. Common Indicated Dividend Payments Increase of $13.1 Billion in Q4 2025 and $46.4 Billion for 2025

    Q4 2025 U.S. common dividend increases were $16.1 billion, up 14.9% from $14.0 billion in Q3 2025 and up 13.0% from $14.2 billion in Q4 2024.Q4 2025 U.S. common dividend decreases were $3.0 billion, down 12.4% from $3.4 billion in Q3 2025 and up 20.5% from $2.5 billion in Q4 2024.Q4 2025 net indicated dividend rate change increased $13.1 billion. For 2025 U.S. common dividend increases were $59.3 billion, down 16.9% from the 2024 period's $71.4 billion; decreases were down 28.8% to $12.9 billion compared to $18.1 billion for the prior 12-month period.The net 2025 indicated dividend increase was $46.4 billion compared to $45.1 billion for the 12-months ending September 2025 and $53.3 billion

    1/7/26 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Dow Jones Indices Announces Change to the S&P/TSX Canadian Dividend Aristocrats Index

    TORONTO, Dec. 22, 2025 /CNW/ - S&P Dow Jones Indices announces the following index change to the S&P/TSX Canadian Dividend Aristocrats Index as a result of the monthly dividend review. Change will be effective prior to the open of trading on Friday, January 2, 2026. S&P/TSX Canadian Dividend Aristocrats Index – January 2, 2026 Symbol COMPANY DELETED AP.UN Allied Properties REIT For more information about S&P Dow Jones Indices, please visit www.spdji.com ABOUT S&P DOW JONES INDICES S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average

    12/22/25 5:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

    SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    11/13/24 10:27:59 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Brookline Bancorp Inc.

    SC 13G/A - BROOKLINE BANCORP INC (0001049782) (Subject)

    11/12/24 5:09:10 PM ET
    $BRKL
    Savings Institutions
    Finance

    Amendment: SEC Form SC 13G/A filed by Brookline Bancorp Inc.

    SC 13G/A - BROOKLINE BANCORP INC (0001049782) (Subject)

    11/12/24 10:03:30 AM ET
    $BRKL
    Savings Institutions
    Finance